Indian Pharma Firms to Launch Diabetes medicine at 90% Lower Cost

A number of Indian pharmaceutical companies are getting ready to release much more affordable generic versions of the diabetes medication empagliflozin. The action comes after Boehringer Ingelheim's patent expired, according to the sources.

The introduction of these affordable substitutes is anticipated to lessen the financial strain of diabetes care for millions of Indian patients. Some of the firms who want to release their versions soon are Mankind Pharma, Torrent, Alkem, Dr. Reddy's, and Lupin.

The fourth-largest pharmaceutical company in India by market share, Mankind Pharma, is reportedly planning to sell empagliflozin for a tenth of the innovator's price of Rs 60 per pill. It is anticipated that the majority of generic versions will cost between Rs 9 and Rs 14 per tablet, making diabetes treatment more affordable. The price cut may have a big effect on the diabetes medication business in India, which has increased from Rs 14,000 crore in 2021 to around Rs 20,000 crore today.

The International Diabetes Federation estimates that 10.1 crore people in India have diabetes. Because there are few possibilities for medical reimbursement, the majority of patients must pay for their treatments out of pocket, putting a significant financial burden on them. Cost-effective treatment solutions are essential because diabetes-related complications further raise costs.

By purchasing three Empagliflozin products from Boehringer Ingelheim last year, Torrent Pharmaceuticals has already solidified its place in this industry. Mankind Pharma is concentrating on affordability in the interim.Cost-effective generic versions of empagliflozin are predicted to change the diabetic medication market in India by increasing competition among pharmaceutical companies and facilitating treatment accessibility.